EDAP TMS SA submitted a 6-K filing on September 9, 2025, reporting strong growth and market opportunities in robotic HIFU therapy, addressing significant conditions like prostate cancer and benign prostatic hyperplasia, indicating a growing market need with 3.3 million American men living with prostate cancer. The company achieved $18.4 million in revenue for the three months ended June 30, 2025, reflecting a 29% compound annual growth rate in HIFU revenue since 2022.